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With the advent of dense maps of human genetic variation, it
is now possible to detect positive natural selection across the
human genome. Here we report an analysis of over 3million
polymorphisms from the International HapMap Project Phase 2
(HapMap2)1. We used ‘long-range haplotype’ methods, which
were developed to identify alleles segregating in a population that
have undergone recent selection2, and we also developed new
methods that are based on cross-population comparisons to dis-
cover alleles that have swept to near-fixation within a population.
The analysis reveals more than 300 strong candidate regions.
Focusing on the strongest 22 regions, we develop a heuristic
for scrutinizing these regions to identify candidate targets
of selection. In a complementary analysis, we identify 26 non-
synonymous, coding, single nucleotide polymorphisms showing
regional evidence of positive selection. Examination of these
candidates highlights three cases in which two genes in a common
biological process have apparently undergone positive selection
in the same population: LARGE and DMD, both related to
infection by the Lassa virus3, in West Africa; SLC24A5 and
SLC45A2, both involved in skin pigmentation4,5, in Europe; and
EDAR and EDA2R, both involved in development of hair follicles6,
in Asia.
An increasing amount of information about genetic variation,
together with new analytical methods, ismaking it possible to explore
the recent evolutionary history of the human population. The first
phase of the International Haplotype Map, including ,1million
single nucleotide polymorphisms (SNPs)7, allowed preliminary
examination of natural selection in humans. Now, with the publica-
tion of the Phase 2 map (HapMap2)1 in a companion paper, over
3million SNPs have been genotyped in 420 chromosomes from three
continents (120 European (CEU), 120 African (YRI) and 180 Asian
from Japan and China (JPT1CHB)).
In our analysis ofHapMap2, we first implemented twowidely used
tests that detect recent positive selection by finding common alleles
carried on unusually long haplotypes2. The two, the Long-Range
Haplotype (LRH)8 and the integrated Haplotype Score (iHS)9 tests,
rely on the principle that, under positive selection, an allele may rise
to high frequency rapidly enough that long-range association with
nearby polymorphisms—the long-range haplotype8—will not have
time to be eliminated by recombination. These tests control for local
variation in recombination rates by comparing long haplotypes to
other alleles at the same locus. As a result, they lose power as selected
alleles approach fixation (100% frequency), because there are then
few alternative alleles in the population (Supplementary Fig. 2 and
Supplementary Tables 1–2).
We next developed, evaluated and applied a new test, Cross
Population ExtendedHaplotypeHomozogysity (XP-EHH), to detect
selective sweeps in which the selected allele has approached or
achieved fixation in one population but remains polymorphic in
the human population as a whole (Methods, and Supplementary
Fig. 2 and Supplementary Tables 3–6). Relatedmethods have recently
also been described10–12.
Our analysis of recent positive selection, using the three methods,
reveals more than 300 candidate regions1(Supplementary Fig. 3 and
Supplementary Table 7), 22 of which are above a threshold such that
no similar events were found in 10Gb of simulated neutrally evolving
sequence (Methods). We focused on these 22 strongest signals
(Table 1), which include two well-established cases, SLC24A5 and
LCT2,5,13, and 20 other regions with signals of similar strength.
The challenge is to sift through genetic variation in the candidate
regions to identify the variants that were the targets of selection. Our
candidate regions are large (mean length, 815 kb; maximum length,
3.5Mb) and often containmultiple genes (median, 4;maximum, 15).
A typical region harbours ,400–4,000 common SNPs (minor allele
frequency.5%), of which roughly three-quarters are represented in
current SNP databases and half were genotyped as part of HapMap2
(Supplementary Table 8).
We developed three criteria to help highlight potential targets of
selection (Supplementary Fig. 1): (1) selected alleles detectable by our
tests are likely to be derived (newly arisen), because long-haplotype
tests have little power to detect selection on standing (pre-existing)
variation14; we therefore focused on derived alleles, as identified by
comparison to primate outgroups; (2) selected alleles are likely to be
highly differentiated between populations, because recent selection is
probably a local environmental adaptation2; we thus looked for
alleles common in only the population(s) under selection; (3)
selected alleles must have biological effects. On the basis of current
knowledge, we therefore focused on non-synonymous coding SNPs
and SNPs in evolutionarily conserved sequences. These criteria are
intended as heuristics, not absolute requirements. Some targets of
selection may not satisfy them, and some will not be in current SNP
databases. Nonetheless, with,50% of common SNPs in these popu-
lations genotyped in HapMap2, a search for causal variants is timely.
We applied the criteria to the regions containing SLC24A5 and
LCT, each of which already has a strong candidate gene, mutation
and trait. At SLC24A5, the 600 kb region contains 914 genotyped
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SNPs. Applying filters progressively (Table 1 and Fig. 1a–d), we
found that 867 SNPs are associated with the long-haplotype signal,
of which 233 are high-frequency derived alleles, of which 12 are
highly differentiated between populations, and of which only 5 are
common in Europe and rare in Asia and Africa. Among these five
SNPs, there is only one implicated as functional by current know-
ledge; it has the strongest signal of positive selection and encodes the
A111T polymorphism associated with pigment differences in
Table 1 | The twenty-two strongest candidates for natural selection
Region Chr:position
(MB, HG17)
Selected population Long Haplotype Test Size (Mb) Total SNPs with
Long Haplotype
Signal
Subset of
SNPs that
fulfil criteria
1
Subset of
SNPs that
fulfil criteria
1 and 2
Subset of SNPs
that fulfil
criteria 1, 2
and 3
Genes at or near SNPs that
fulfil all three criteria
1 chr1:166 CHB1 JPT LRH, iHS 0.4 92 39 30 2 BLZF1, SLC19A2
2 chr2:72.6 CHB1 JPT XP-EHH 0.8 732 250 0 0
3 chr2:108.7 CHB1 JPT LRH, iHS, XP-EHH 1.0 972 265 7 1 EDAR
4 chr2:136.1 CEU LRH, iHS, XP-EHH 2.4 1,213 282 24 3 RAB3GAP1, R3HDM1, LCT
5 chr2:177.9 CEU,CHB1 JPT LRH, iHS, XP-EHH 1.2 1,388 399 79 9 PDE11A
6 chr4:33.9 CEU,YRI, CHB1 JPT LRH, iHS 1.7 413 161 33 0
7 chr4:42 CHB1 JPT LRH, iHS, XP-EHH 0.3 249 94 65 6 SLC30A9
8 chr4:159 CHB1 JPT LRH, iHS, XP-EHH 0.3 233 67 34 1
9 chr10:3 CEU LRH, iHS, XP-EHH 0.3 179 63 16 1
10 chr10:22.7 CEU, CHB1 JPT XP-EHH 0.3 254 93 0 0
11 chr10:55.7 CHB1JPT LRH, iHS, XP-EHH 0.4 735 221 5 2 PCDH15
12 chr12:78.3 YRI LRH, iHS 0.8 151 91 25 0
13 chr15:46.4 CEU XP-EHH 0.6 867 233 5 1 SLC24A5
14 chr15:61.8 CHB1 JPT XP-EHH 0.2 252 73 40 6 HERC1
15 chr16:64.3 CHB1 JPT XP-EHH 0.4 484 137 2 0
16 chr16:74.3 CHB1 JPT, YRI LRH, iHS 0.6 55 35 28 3 CHST5, ADAT1, KARS
17 chr17:53.3 CHB1 JPT XP-EHH 0.2 143 41 0 0
18 chr17:56.4 CEU XP-EHH 0.4 290 98 26 3 BCAS3
19 chr19:43.5 YRI LRH, iHS, XP-EHH 0.3 83 30 0 0
20 chr22:32.5 YRI LRH 0.4 318 188 35 3 LARGE
21 chr23:35.1 YRI LRH, iHS 0.6 50 35 25 0
22 chr23:63.5 YRI LRH, iHS 3.5 13 3 1 0
Total SNPs 16.74 9,166 2,898 480 41
Twenty-two regions were identified at a high threshold for significance (Methods), based on the LRH, iHS and/or XP-EHH test. Within these regions, we examined SNPs with the best evidence of
being the target of selection on the basis of having a long haplotype signal, and by fulfilling three criteria: (1) being a high-frequency derived allele; (2) being differentiated between populations and
commononly in the selected population; and (3) being identified as functional by current annotation. Several candidate polymorphisms arise from the analysis includingwell-known LCT and SLC24A5
(ref. 2), as well as intriguing new candidates.
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Figure 1 | Localizing SLC24A5 and EDAR signals of selection.
a–d, SLC24A5. a, Strong evidence for positive selection in CEU samples at a
chromosome 15 locus: XP-EHH between CEU and JPT1CHB (blue), CEU
and YRI (red), and YRI and JPT1CHB (grey). SNPs are classified as having
low probability (bordered diamonds) and high probability (filled diamonds)
potential for function. SNPs were filtered to identify likely targets of
selection on the basis of the frequency of derived alleles (b), differences
between populations (c) and differences between populations for high-
frequency derived alleles (less than 20% in non-selected populations)
(d). The number of SNPs that passed each filter is given in the top left corner
in red. The threonine to alanine candidate polymorphism in SLC24A5 is the
clear outlier. e–h, EDAR. e, Similar evidence for positive selection in
JPT1CHB at a chromosome 2 locus: XP-EHH between CEU and
JPT1CHB (blue), between YRI and JPT1CHB (red), and between CEU
and YRI (grey); iHS in JPT1CHB (green). A valine to alanine
polymorphism in EDAR passes all filters: the frequency of derived alleles
(f), differences between populations (g) and differences between
populations for high-frequency derived alleles (less than 20% in non-
selected populations) (h). Three other functional changes, a DRE change in
SULT1C2 and two SNPs associated with RANBP2 expression (Methods),
have also become common in the selected population.
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humans and thought to be the target of positive selection5. Our
criteria thus uniquely identify the expected allele.
At the LCT locus, we found similar degrees of filtration. Within
the 2.4Mb selective sweep, 24 polymorphisms fulfil the first two
criteria (Table 1, and Supplementary Fig. 4), with the polymorphism
thought to confer adult persistence of lactase among them. However,
this SNP was only identified as functional after extensive study of the
LCT gene15. Thus LCT shows both the utility and the limits of the
heuristics.
Given the encouraging results for SLC24A5 and LCT, we per-
formed a similar analysis on all 22 candidate regions (Table 1).
Filtering the 9,166 SNPs associated with the long-haplotype signal,
we found that 480 satisfied the first two criteria. We identified 41 out
of the 480 SNPs (0.2% of all SNPs genotyped in the regions) as
possibly functional on the basis of a newly compiled database of
polymorphisms in known coding elements, evolutionarily conserved
elements and regulatory elements (Methods; B.F., unpublished),
together containing , 5.5% of all known SNPs.
Eight of the forty-one SNPs encode non-synonymous changes
(Table 1 and Supplementary Table 9). Apart from the well-known
case of SLC24A5, they are found in EDAR, PCDH15, ADAT1, KARS,
HERC1, SLC30A9 and BLFZ1. The remaining 33 potentially func-
tional SNPs lie within conserved transcription factor motifs, introns,
UTRs and other non-coding regions.
To identify additional candidates, we reversed the process by
taking non-synonymous coding SNPs with highly differentiated
high-frequency derived alleles; these SNPs comprise a tiny fraction
of all SNPs and have a higher a priori probability of being targets of
selection. Of the 15,816 non-synonymous SNPs in HapMap2, 281
(Supplementary Table 10) have both a high derived-allele frequency
(frequency .50%) and clear differentiation between populations
(FST is in the top 0.5 percentile). We examined these 281 SNPs to
identify those embedded within long-range haplotypes16, and
identified 26 putative cases of positive selection. These include the
eight non-synonymous SNPs identified in the genome-wide analysis
above.
Interestingly, analysis of the top regions and the non-synonymous
SNPs together revealed three cases of two genes in the same pathway
both having strong evidence of selection in a single population.
In the European sample, there is strong evidence for two genes
already shown to be associated with skin pigment differences among
humans. The first is SLC24A5, described above.We further examined
the global distribution (Fig. 2) and the predicted effect on protein
activity of the SLC24A5 A111T polymorphism (Supplementary Fig.
5, 6). The second, SLC45A2, has an important role in pigmentation in
zebrafish, mouse and horse4. An L374F substitution in SLC45A2 is
at 100% frequency in the European sample, but absent in the Asian
and African samples. A recent association study has shown that the
Phe-encoding allele is correlated with fair skin and non-black hair in
Europeans4. Together, the data support SLC45A2 as a target of
positive selection in Europe10,17.
In the African sample (Yoruba in Ibadan, Nigeria), there is evid-
ence of selection for two genes with well-documented biological links
to the Lassa fever virus. The strongest signal in the genome, on the
basis of the LRH test, resides within a 400 kb region that lies entirely
within the gene LARGE. The LARGE protein is a glycosylase that
post-translationally modifies a-dystroglycan, the cellular receptor
for Lassa fever virus (as well as other arenaviruses), and the modi-
fication has been shown to be critical for virus binding3. The virus
name is derived from Lassa, Nigeria, where the disease is endemic,
with 21% of the population showing signs of exposure18. We also
noted that the DMD locus is on our larger candidate list of regions,
with the signal of selection again in the Yoruba sample.DMD encodes
a cytosolic adaptor protein that binds toa-dystroglycan and is critical
for its function. We hypothesize that Lassa fever created selective
pressure at LARGE and DMD12. This hypothesis can be tested by
correlating the geographical distribution of the selected haplotype
with endemicity of the Lassa virus, studying infection of genotyped
cells in vitro, and searching for an association between the selected
haplotype and clinical outcomes in infected patients.
In the Asian samples, we found evidence of selection for non-
synonymous polymorphisms in two genes in the ectodysplasin
(EDA) pathway, which is involved in development of hair, teeth
and exocrine glands6. The genes are EDAR and EDA2R, which encode
the key receptors for the ligands EDA A1 and EDA A2, respectively.
Notably, the EDA signalling pathway has been shown to be under
positive selection for loss of scales in multiple distinct populations of
freshwater stickleback fish19. A mutation encoding a V370A substi-
tution in EDAR is near fixation in Asia and absent in Europe and
Africa (Fig. 1e–h). An R57K substitution in EDA2R has derived-allele
frequencies of 100% in Asia, 70% in Europe and 0% in Africa.
The EDAR polymorphism is notable because it is highly differen-
tiated between the Asian and other continental populations (the 3rd
most differentiated among 15,816 non-synonymous SNPs), and also
within Asian populations (in the top 1% of SNPs differentiated
between the Japanese and Chinese HapMap samples). Genotyping
of the EDAR polymorphism in the CEPH (Centre d’Etudie du
Polymorphisme Humain) global diversity panel20 shows that it is at
high but varying frequency throughout Asia and the Americas (for
example, 100% in Pima Indians and in parts of China, and 73% in
Japan) (Fig. 2, and Supplementary Fig. 7). Studying populations like
the Japanese, in which the allele is still segregating, may provide clues
to its biological significance.
EDAR has a central role in generation of the primary hair follicle
pattern, and mutations in EDAR cause hypohidrotic ectodermal
a
b
Derived allele (C)
Ancestral allele (T)
Pima Indians
JapanChina
Cambodia
EDAR
Derived allele (A)
Ancestral allele (G)
SLC24A5
Europe
Pakistan
Algeria
Figure 2 | Global distribution of SLC24A5 A111T and EDAR V370A.
Worldwide allele-frequency distributions for candidate polymorphisms
with the strongest evidence for selection20. a, SLC24A5A111T is common in
Europe,NorthernAfrica andPakistan, but rare or absent elsewhere.b,EDAR
V370A is common in Asia and the Americas, but absent in Europe and
Africa.
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dysplasia (HED) in humans andmice, characterized by defects in the
development of hair, teeth and exocrine glands6. The V370A poly-
morphism, proposed to be the target of selection, lies within EDAR’s
highly conserved death domain (Supplementary Fig. 8), the location
of the majority of EDAR polymorphisms causing HED21. Our struc-
tural modelling predicts that the polymorphism lies within the bind-
ing site of the domain (Fig. 3).
Our analysis only scratches the surface of the recent selective
history of the human genome. The results indicate that individual
candidates may coalesce into pathways that reveal traits under selec-
tion, analogous to the alleles of multiple genes (for example, HBB,
G6PD and DARC) that arose and spread in Africa and other tropical
populations as a result of the partial protection they confer against
malaria2,12. Such endeavours will be enhanced by continuing
development of analytical methods to localize signals in candidate
regions, generation of expanded data sets, advances in comparative
genomics to define coding and regulatory regions, and biological
follow-up of promising candidates. True understanding of the role
of adaptive evolution will require collaboration across multiple dis-
ciplines, including molecular and structural biology, medical and
population genetics, and history and anthropology.
METHODS SUMMARY
Genotyping data. Phase 2 of the International Haplotype Map (HapMap2)
(www.hapmap.org) contains 3.1million SNPs genotyped in 420 chromosomes
in 3 continental populations (120 European (CEU), 120 African (YRI) and 180
Asian (JPT1CHB))1. We further genotyped our top HapMap2 functional can-
didates in the HGDR-CEPH Human Genome Diversity Cell Line Panel20.
LRH, iHS and XP-EHH tests. The Long-Range Haplotype (LRH), integrated
Haplotype Score (iHS) andCross Population EHH (XP-EHH) tests detect alleles
that have risen to high frequency rapidly enough that long-range association
with nearby polymorphisms—the long-range haplotype—has not been eroded
by recombination; haplotype length is measured by the EHH8,9. The first two
tests detect partial selective sweeps, whereas XP-EHHdetects selected alleles that
have risen to near fixation in one but not all populations. To evaluate the tests, we
simulated genomic data for eachHapMap population in a range of demographic
scenarios—under neutral evolution and twenty scenarios of positive selection—
developing the program Sweep (www.broad.mit.edu/mpg/sweep) for analysis.
For our top candidates by the three tests, we tested for haplotype-specific recom-
bination rates and copy-number polymorphisms, possible confounders.
Localization.We calculated FST and derived-allele frequency for all SNPs within
the top candidate regions.We developed a database for those regions to annotate
all potentially functional DNA changes (B.F., unpublished), including non-
synonymous variants, variants disrupting predicted functional motifs, variants
within regions of conservation in mammals and variants previously associated
with human phenotypic differences, as well as synonymous, intronic and
untranslated region variants.
Structural model.We generated a homology model of the EDAR death domain
(DD) from available DD structures using Modeller 9v1 (ref. 22). The distri-
bution of conserved residues, built using ConSurf23 with an EDAR sequence
alignment from 22 species, shows a bias to the protein core in helices H1, H2
and H5, supporting our model.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
Received 8 August; accepted 13 September 2007.
1. The International HapMap Consortium. A second generation human haplotype
map of over 3.1 million SNPs. Nature doi:10.1038/nature06258 (this issue).
2. Sabeti, P. C. et al. Positive natural selection in the human lineage. Science 312,
1614–1620 (2006).
3. Kunz, S. et al. Posttranslational modification of a-dystroglycan, the cellular
receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus
binding. J. Virol. 79, 14282–14296 (2005).
4. Graf, J., Hodgson, R. & van Daal, A. Single nucleotide polymorphisms in theMATP
gene are associated with normal human pigmentation variation. Hum. Mutat. 25,
278–284 (2005).
5. Lamason, R. L. et al. SLC24A5, a putative cation exchanger, affects pigmentation
in zebrafish and humans. Science 310, 1782–1786 (2005).
6. Botchkarev, V. A. & Fessing, M. Y. Edar signaling in the control of hair follicle
development. J. Investig. Dermatol. Symp. Proc. 10, 247–251 (2005).
7. The International Haplotype Map Consortium. A haplotype map of the human
genome. Nature 437, 1299–1320 (2005).
8. Sabeti, P. C. et al. Detecting recent positive selection in the human genome from
haplotype structure. Nature 419, 832–837 (2002).
9. Voight, B. F., Kudaravalli, S., Wen, X. & Pritchard, J. K. A map of recent positive
selection in the human genome. PLoS Biol. 4, e72 (2006).
10. Kimura, R., Fujimoto, A., Tokunaga, K. & Ohashi, J. A practical genome scan for
population-specific strong selective sweeps that have reached fixation. PLoS ONE
2, e286 (2007).
11. Tang, K., Thornton, K. R. & Stoneking, M. A new approach for using genome scans
to detect recent positive selection in the human genome. PLoS Biol. 5, e171 (2007).
12. Williamson, S. H. et al. Localizing recent adaptive evolution in the human genome.
PLoS Genet. 3, e90 (2007).
13. Bersaglieri, T. et al. Genetic signatures of strong recent positive selection at the
lactase gene. Am. J. Hum. Genet. 74, 1111–1120 (2004).
14. Teshima, K. M., Coop, G. & Przeworski, M. How reliable are empirical genomic
scans for selective sweeps? 16, 702–712 Genome Res. (2006).
15. Kuokkanen, M. et al. Transcriptional regulation of the lactase–phlorizin hydrolase
gene by polymorphisms associated with adult-type hypolactasia. Gut 52,
647–652 (2003).
16. Miller, R. G. Simultaneous statistical inference XVI 299 (Springer, New York, 1981).
17. Soejima, M., Tachida, H., Ishida, T., Sano, A. & Koda, Y. Evidence for recent
positive selection at the human AIM1 locus in a European population. Mol. Biol.
Evol. 23, 179–188 (2006).
18. Richmond, J. K. & Baglole, D. J. Lassa fever: epidemiology, clinical features, and
social consequences. Br. Med. J. 327, 1271–1275 (2003).
19. Colosimo, P. F. et al. Widespread parallel evolution in sticklebacks by repeated
fixation of Ectodysplasin alleles. Science 307, 1928–1933 (2005).
Potential 
binding region
V370A
R420Q
T413P
I418T
L377F
T403M
G382S
R375H
N
C
Figure 3 | Structural model of the EDAR death domain. Ribbon
representation of a homology model of the EDAR death domain (DD),
based on the alignment of the EDAR DD amino acid sequence (EDAR
residues 356–431), with multiple known DD structures. The helices are
labelled H1 to H6. Residues in blue (the H1–H2 and H5–H6 loops, residues
370–376 and 419–425, respectively) correspond to the homologous
residues in Tube that interact with Pelle in the Tube-DD–Pelle-DD
structure24. These EDAR-DD residues therefore form a potential region of
interaction with a DD-containing EDAR-interacting protein, such as
EDARADD. The V370A polymorphic residue (red) is located prominently
within this potential binding region in the H1–H2 loop. Seven of the
thirteen known mis-sense mutations in EDAR that lead to hypohidrotic
ectodermal dysplasia (HED) in humans are located in the EDAR-DD: the
only four mutations in EDAR that lead to the dominant transmission of
HED (green) and three recessive mutations (yellow)21. Four of these
mutations, R375H, L377F, R420Q and I418T are located in the vicinity of
the predicted interaction interface.
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METHODS
Genotyping data.The chromosomes examined inHapMap 2were phased by the
consortium using PHASE25.
The HGDR-CEPH Human Genome Diversity Cell Line Panel20 consists of
1,051 individuals from 51 populations across the world. We obtained DNA for
the panel from the Foundation Jean Dausset (CEPH) and genotyped our top
functional candidates for selection in the panel.
LRH, iHS, and XP-EHH tests. The Long-Range Haplotype (LRH) and the
integrated Haplotype Score (iHS) tests have been previously described8,9 and
our methods are given in Supplementary Methods.
EHH between two SNPs, A and B, is defined as the probability that two
randomly chosen chromosomes are homozygous at all SNPs between A and B,
inclusive8; it is usually calculated using a sample of chromosomes from a single
population. Explicitly, if the N chromosomes in a sample form G homozygous
groups, with each group i having ni elements, EHH is defined as
EHH~
PG
i~1
ni
2
 
N
2
 
The XP-EHH test detects selective sweeps in which the selected allele has risen
to high frequency or fixation in one population, but remains polymorphic in the
human population as a whole; for this purpose it is more powerful than either
iHS or LRH (Supplementary Fig. 2 and Supplementary Tables 3–6). XP-EHH
uses cross-population comparison of haplotype lengths to control for local vari-
ation in recombination rates. Such cross-population comparison is complicated
by the fact that haplotype lengths also depend on population history, such as
bottlenecks and expansions26. The XP-EHH test normalizes for genome-wide
differences in haplotype length between populations.
We define the XP-EHH test with respect to two populations, A and B, a given
core SNP and a given direction (centromere distal or proximal). EHH is calcu-
lated for all SNPs in population A between the core SNP and X, and the value
integrated with respect to genetic distance, with the result defined as IA. IB is
defined analogously for populationB. The statistic ln(IA/IB) is then calculated; an
unusually positive value suggests selection in population A, a negative value
selection in B. For identifying outliers, the log-ratio is normalized to have zero
mean and unit variance. Details are given in Supplementary Methods.
We developed a computer program, Sweep, to implement these tests (LRH,
iHS and XP-EHH) for positive selection, (SupplementaryMethods; www.broad.
mit.edu/mpg/sweep). In identifying the 22 strongest candidate regions, we con-
sidered regions with signals in at least two of five tests (LRH, iHS andXP-EHH in
the three pairwise comparisons among the three populations), as well as those
that had the strongest signal for each individual test. With this threshold we
found no events in 10Gb of simulated neutrally evolving sequence. For the top
candidates by the three tests, we have taken additional steps to rule out the effects
of recombination rate variation and copy number polymorphisms (Supple-
mentary Methods).
Simulations and power calculations.We simulated the evolution of 1MB sec-
tions of 120 chromosomes from each of the three continental HapMap popula-
tions, using a previously validated demographic model27, under neutrality and
under twenty scenarios of positive selection. We studied the effects of demo-
graphy by further simulating recent bottlenecks with a range of intensity. Details
of simulations and power calculations are given in Supplementary Methods.
Functional annotation.Wedeveloped an annotation database for our candidate
regions to identify all DNA changes with potential functional consequence (B.F.,
unpublished).We first examined candidatesmost likely to be functional, includ-
ing non-synonymous mutations, variants that disrupt predicted functional
motifs (transcription factormotifs in conserved regions up to 10-kb 59 of known
genes and miRNA binding-site motifs in conserved 39 untranslated regions of
known genes), and variations reported to be associated with human phenotypic
differences. For the last category, we identified variations associated with a
clinical state (for example, malaria resistance) by a review of the published
literature and those associated with changes to gene expression in lymphoblas-
toid cell lines from the HapMap individuals. The annotation included insertion/
deletion mutations of all sizes. We also examined candidates with lower prob-
ability of being functional, including synonymous, intronic and untranslated
variations and those that occur within regions of conservation in mammalian
species. These methods are described in greater detail in Supplementary
Methods.
Structural model of EDAR’s death domain. We generated a homology model
for EDAR’s death domain (DD) using six solved DD structures: p75 NGFR-DD,
RAIDD-DD, Pelle-DD, FADD-DD, Fas-DD and IRAK4-DD24,28–32. We aligned
the corresponding protein sequences using SALIGN33.We then added the amino
acid sequence of EDAR’s DD (residues 356–431) to this structural alignment
using Modeller 9v1 (ref. 22). The resulting alignment was used as the input to
Modeller 9v1 to build ten EDAR-DD structure models, and the best model was
selected based on the Objective Function Score. Owing to the high DOPE scores
in the H1–H2 loop we performed a loop refinement using Modeller9v1, signifi-
cantly reducing the energy of this region. We further evaluated the model by
examining the distribution of conserved residues using ConSurf23 with an align-
ment of EDAR-DD sequences from 22 species. We observed a bias of conserved
residues to the protein core in H1, H2 and H5, which supports our EDAR-DD
model. To identify potential binding regions of EDAR-DD, we used LSQMAN34
to superimpose the model to the Tube-DD–Pelle-DD complex structure24. The
H1–H2 and H5–H6 loops of the EDAR-DD correspond to Tube residues inter-
acting with Pelle, andH2–H3 andH4–H5 loops to Pelle residues interactingwith
Tube. We focused our analysis on the residues corresponding to the interacting
region in Tube because our EDAR-DD model is most similar to Tube. Figures
were generated with PyMOL35.
Other analysis. Description of methods for calculating FST, derived-allele fre-
quency, alignment of the SLC24 amino acids, species alignments, conservation
graphs, and estimation of the fraction of SNPs genotyped in HapMap2 and
identified in dbSNP, are given in Supplementary Methods.
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